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ABSTRACT  
Metabolic Syndrome is a cluster of vascular risk factors which has been related to 
dementia and cognitive decline. The aim of this study was to describe the 
neuropsychological profile of Metabolic Syndrome patients. An extensive 
neuropsychological protocol was administered to 55 patients and 35 controls 
assessing memory, executive, visuoperceptual and visuoconstructive functions, 
language and speed of processing. There were differences between groups in 
speed of processing and some executive functions after controlling for the 
influences of education and gender. The results suggest that Metabolic Syndrome 









At the beginning of the twentieth century, Kylin described a syndrome which 
included hypertension, hyperglycemia and hyperuricemia (1). Over the last twenty 
years the syndrome has been studied by various disciplines and has received 
different names: the “deadly quartet” (2), hypertriglyceridemic waist (3), X 
syndrome, or insulin resistance (4). At present the most widely-used name is 
Metabolic Syndrome (MetSd), which has been defined by the National Cholesterol 
Education Program (NCEP) (5) as the presence of at least three of the following 
vascular risk factors: hypertension, hyperglycemia, hypertriglyceridemia, low 
levels of high-density lipoprotein (HDL) cholesterol, and obesity as measured by 
waist circumference (Supplementary data 1). 
To date, several epidemiological studies have highlighted the effects of vascular 
risk factors on cognition (6), and there is some evidence of the neuropsychological 
effects of obesity (7), impaired fasting glucose (8), dyslipemia (9) and hypertension 
(10), as individual vascular risk factors of the syndrome. 
Yaffe et al. (2004) reported that MetSd patients obtained lower Mini Mental State 
Examination (MMSE) scores than healthy people. MetSd patients also showed a 
decline in memory and MMSE scores in a three-year follow-up (11).  A prospective 
cohort study of cardiovascular disease performed in 1965 and in 1991 (12) reported 
an association between the presence of vascular risk factors at baseline with 
evolution to dementia after a 25-year period in MetSd patients. More recently, 
studies have linked MetSd to a higher risk of Alzheimer’s disease (13), fronto-
subcortical symptoms, and poorer neuropsychological performance associated with 
ageing (14,15). However, some authors have reported better cognitive 
performance in very old people with MetSd (16,17),   
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To our knowledge, most studies of MetSd are cross-sectional (29, 32) and use 
regression analysis to evaluate the association between the syndrome and 
cognitive decline. Only a few of them include an extensive neuropsychological 
assessment of MetSd patients.  
The aim of the present study was to investigate the neuropsychological impairment 
of MetSd using a case-control design in which the control group did not manifest 
any of the risk factors included in the syndrome. We hypothesized that MetSd 
patients would show a specific cognitive profile, due to the combined effects of 
vascular risk factors on the brain. Specifically, this profile would probably reflect 
the impact of the syndrome on white matter (WM) integrity. Therefore, MetSd 
patients may show differences in processing speed and in correct performance of 
executive functions.  
 
MATERIALS AND METHODS 
Research participants 
A medical team reviewed the medical records of 600 patients from two public 
medical centers of Barcelona province (Centres d’atenció primària) in Cerdanyola 
del Vallés and Sant Just Desvern, Barcelona (Spain). All the participants were 
volunteers, right handed, aged between 50 and 80 years old, and literate. The 
exclusion criteria were: uncorrected visual or auditory deficits, drug abuse or 
alcoholism (more than 28 standard drink units per week for men and more than 17 
standard drink units per week for women (18)), a history of developmental 
pathology, and current neurological, hematological, hormonal, nutritional 
pathology and/or neoplasm. All selected participants also completed a screening 
interview in order to check the medical information from their records, to measure 
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their general cognitive capacity according to MMSE score (19) and to estimate their 
intelligence coefficient using the Vocabulary subtest of the Wechsler Adult 
Intelligence Scale—3rd edition (WAIS-III) (19). In the same session participants also 
underwent a modified interview based on the Structured Clinical Interview for 
DSM-IV Axis I disorders (20) to exclude major psychiatric diseases. Subjects with an 
MMSE score below 26 and estimated intelligence coefficients below 85 were 
excluded. Praxis skills were preserved in the whole sample and were assessed by 
bilateral imitation of hand positions (19). Hand dominance was assessed by 
Edinburgh test (19). Years of education and occupational level (low, medium or 
high) were also recorded.  
Ninety volunteers were finally selected, 55 of whom fulfilled the criteria for MetSd 
as described by the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III (ATP-III) (5). Measures of glucose, HDL-cholesterol and 
triglycerides for all participants were obtained by a blood test; blood test analyses 
were performed in the reference laboratory of each medical center. Blood 
pressure measures and waist circumference of participants were recorded during 
the screening sessions. The final sample comprised a patient group of 36 women 
and 19 men with a mean age of 63.80 years (SD 7.3) and mean of 8.55 years of 
education (SD 3.6), and 35 healthy controls without any of the vascular risk factors 
included in the MetSd criteria. The controls were 17 women and 18 men, with a 
mean age of 61.66 (SD 7.7) and a mean of 10.20 years of education (SD 4.56). All 
enrolled subjects signed an informed consent form prior to taking part in the 




Neuropsychological assessment  
All participants underwent a comprehensive neuropsychological evaluation. The 
tests were administered by a trained neuropsychologist in a fixed order during two 
90-min sessions.   
Verbal memory was assessed by Rey’s Auditory Verbal Learning Test (RAVLT) (19).  
The RAVLT variables computed were total learning (sum of correct responses from 
trial I to trial V), delayed memory recall after 20 min (VI) and retroactive 
interference, which was defined as the influence of new learning (list b) on the 
previously achieved learning (list a) (19). Visual memory was assessed by the Faces 
I subtest of the Wechsler Memory Scale III (WMS-III) (19).  
Immediate memory span was evaluated with the forward digit scores of the Digit 
subtest of the WAIS-III, while measures of working memory were based on 
backward digit scores of the Digit subtest and the Arithmetic subtest of the WAIS III 
(19). 
Visuoperceptual and visuoconstructive functions were evaluated by the number of 
correct items on the Benton Facial Recognition Test—Short Form (19) and the score 
on the Block Design subtest of the WAIS-III (19) respectively.  
The short-form version of the Wisconsin Card Sorting Test (19) and part B of the 
Trail Making Test (19) were administered to evaluate high level executive 
functions. On the WCST, perseverative errors and the total number of categories 
obtained were recorded.   
Verbal fluency was measured by the number of words produced within two 
restricted categories: semantic (animals) and phonemic (beginning with the letter 
“p”), within a 1-min limit. The Stroop test (19) was administered to obtain a 
measure of interference response.  
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The processing speed variables used were total correct responses in 90 s on the 
orally-administered Symbol Digit Modalities Test (SDMT) (19) number of seconds 
taken to solve the Trail Making Test Part A, time taken to complete the Grooved 
Pegboard Test (19) with the dominant and non-dominant hands, and reaction time 
in CPT-II (Continuous Performance Test II) (19). 
Finally, the total number of correct responses on the short form of the Boston 
Naming Test (Spanish version) was used to assess language (19).  
 
Statistical analysis  
Demographic and neuropsychological differences between groups were compared 
using the Statistical Package for the Social Sciences (SPSS WIN; v.14.0). The 
Student’s t test or its non-parametric equivalent, the Mann-Whitney U test, were 
used for quantitative variables when required, while the χ 2 test was used to 
analyze qualitative variables. Effects of education and gender were controlled by 
an analysis of covariance (ANCOVA) of significant variables; some of them were 
converted to guarantee the ANCOVA assumptions.  The magnitude of the observed 
effect was calculated by the r effect size. The discriminative power of the 
neuropsychological test between MetSd patients and controls was determined by a 
discriminant analysis (21) in which we included the significant tests obtained in the 
group comparison analysis, using a stepwise method. 
 
RESULTS 
There were no differences between the groups in age (t=1.3 p=0.186), education 
(U=737, p=0.059), occupational level (χ 2= 3.2 p=0.198), scores on the Vocabulary 
subtest (t=-1.4, p=0.152) or gender (χ 2=2.5, p=0.113). Detailed description of the 
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sample can be found in supplementary data 2. More than half of the sample  
(56.3%) fulfilled three of the MetSd diagnostic criteria, 27.3% met four criteria, 
and 16.4% fulfilled five. The most prevalent vascular risk factor among patients 
was obesity (92.7%), followed by hypertension (76.4%), low levels of HDL 
cholesterol (75%), fasting glucose (69.1%) and hypertriglyceridemia (48.1%) 
(Supplementary data 3) 
The group comparison analyses showed significant differences in some cognitive 
functions (Table 1). Specifically, we found a reduction in processing speed and 
poor results in some executive functions. Several neuropsychological differences 
between patients and controls remained significant after controlling for the effect 
of education and gender through ANCOVA. The differences were significant for GPT 
dominant (F=11.9, p= 0.001) and non-dominant hand (F=12.9, p=0.001), retroactive 
interference of RAVLT (F= 4.4, p= 0.040), semantic fluency (F=4.4, 0.039) and 
Arithmetic subtest of WAIS-III (F= 4.5, p=0.039).  
We entered the variables that achieved significance on group comparison into a 
discriminant analysis. Reaction time on the CPT-II and the Block Design subtest 
were the variables with the best power to differentiate between patients and 
controls. These tests correctly classified 71.4% of the patients and 53.8% of the 
controls (Supplementary data 4). 
 
DISCUSSION 
The results of this study show that MetSd involves a decrease in cognitive 
performance. Specifically, the neuropsychological profile of MetSd patients is 
characterized by dysfunction in two cognitive domains: slowness in mental 
processing and executive dysfunctions.   
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Processing speed is assessed by GPT dominant and non-dominant hand. We 
measured the time taken to insert all the pegs necessary to fill a table with four or 
five holes, using first the dominant hand and then the non-dominant hand.  
Mild executive dysfunction is evidenced by several measures: retroactive 
interference, semantic fluency and arithmetic subtest on the WAIS-III. Retroactive 
interference is calculated by subtracting the trial V score from the trial VI score on 
the RAVLT. This score shows the interference effect of new material in the recall 
of previous learning. The semantic fluency test measures the number of words 
(names of animals) elicited in 1 minute; a poor semantic fluency is related to 
difficulties in retrieval strategies. Finally, the arithmetic subtest on the WAIS-III 
requires the ability to solve verbal arithmetic problems presented in a story 
format. This test assesses the ability to organize the elements of the problems as 
well as working memory and attention resources. (19) 
The differences between patients and controls remained after controlling for the 
possible effect of education and gender. In contrast, several cognitive functions 
remained unaffected by the syndrome. We found non-significant differences in: 
visuoperceptual and visuospatial abilities, assessed by the Benton Facial 
Recognition Test—Short Form, verbal learning and long term recall measured by 
RAVLT, and high-level executive functions tested by WCST, TMT B and Stroop test.  
Our results corroborate previous findings from studies that investigated isolated 
vascular risk factors (6-10). Processing speed deficits and executive dysfunctions 
have been reported in patients with vascular risk factors and in subjects without 
cognitive impairment which progress to vascular cognitive impairment (22). Dik et 
al. (2007) (15) showed a relationship between MetSd and processing speed, 
immediate recall, fluid intelligence and the MMSE score in a cross-sectional study. 
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However, in this study the general cognitive level was not controlled: we provide 
evidence for the specificity of speed of mental processing and executive 
dysfunctions in MetSd. 
Our results agree with those of van der Berg et al., (2008) (23), who compared 
three groups, a control group, a group of MetSd patients, and a group of patients 
with type 2 diabetes (DM-II). Those authors found poorer performance in 
processing speed in both patient groups in comparison to controls. The processing 
speed was measured by a composite score of Trail Making Test Part A, the Stroop 
Color-Word Test (parts I and II), and the Digit Symbol subtest of the WAIS-III.  
They also found poorer cognitive performance in the DM-II group. This group 
showed additional differences in executive functioning assessed by a composite 
score of Trail Making Test Part B, the Stroop Color-Word Test (part III), the Brixton 
Spatial Anticipation Test, and semantic and phonetic verbal fluencies. Both patient 
groups had very similar vascular risk factor profiles, apart from their glucose 
metabolism, indicating that the risk factors clustered in the metabolic syndrome 
may play a role in the decreases in cognitive functioning in DMII patients, and that 
these decreases may even develop in prediabetic stages. However, in this study 
the control group included subjects with vascular risk factors. In our healthy 
group, we controlled this aspect by including only subjects without any of the risk 
factors for MetSd. This may have been the reason for our results, we found both 
deficits, mental slowness and mild executive dysfunction, in our metabolic 
syndrome group.  
One possible explanation for the cognitive impairment in our sample is subcortical 
brain damage produced by silent vascular pathology. MetSd is associated both with 
atherosclerosis (24) and with increased cellular oxidative stress (25). The 
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molecular and structural alterations in MetSd are the consequence of the presence 
of vascular risk factors. In fact this syndromic effect has been described previously 
in relation to the risk of suffering stroke and coronary diseases (26), and has been 
associated with intracranial atherosclerosis (27), which may be the cause of small-
vessel disease.  
Although there is no direct proof of vascular involvement in the neuropsychological 
impairment reported in the present sample, a diffusion tensor imaging (DTI) study 
performed in a subsample of 38 of our 90 subjects indicated microstructural WM 
alterations in patients with MetSd mainly involving the frontal lobe. Patients with 
MetSd showed an anterior-posterior pattern of deterioration in WM with reduced 
fractional anisotropy (FA) and increased apparent diffusion coefficient (ADC) 
values compared to controls. WM changes were not related to any isolated vascular 
risk factor (28). Although the specific mechanism of this damage is not clear, the 
use of this non-invasive method provides information on subtle WM changes. Small-
vessel disease could be responsible for the microstructural alteration, due to the 
chronic state of vascular dysregulation in the brain. Therefore, the consequences 
of MetSd in vascular dysregulation may be taken as representing a specific 
neuropsychological profile. Indeed, DTI results of previous studies are in 
agreement with our neuropsychological findings: WM degeneration associated to 
aging, specifically in the frontal lobe, is related to slower processing and working 
memory deficits (29). Therefore, the anterior-predominance in the deterioration 
agrees with the neuropsychological deficit observed in our sample of patients. 
Similarly, the preservation of other cognitive domains assessed indicated the 
integrity of posterior parts of the brain and their connections.  
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 Our results suggest that MetSd is a prodromal state for mild vascular cognitive 
impairment, in the sense that it implies a specific cognitive profile with 
attentional and executive function deficits (30) as well as psychomotor slowness 
and immediate memory deficits.  
Nordlund et al. (2007)(31) found significant differences between vascular MCI and 
non-vascular MCI subjects in executive functions, speed, attention and language. 
in a sample that included subjects with stroke and transitory ischemic attack, 
Sachdev et al. (2004)(32) reported similar results: they found that vascular MCI 
patients differed from controls in executive functions, information processing 
speed, visual memory, abstraction, and visuoconstruction. In this connection, our 
results showing a specific neuropsychological profile with processing speed deficit 
and executive dysfunctions indicate a prodromal state of vascular cognitive 
impairment. Longitudinal studies are required to elucidate whether MetSd may be 
a prior stage of vascular cognitive impairment. Follow-up studies of these patients 
are therefore of great interest. 
Previous studies of MetSd (16,23) compared patients with the syndrome with 
normal controls, but they did not exclude all the vascular risk factors associated 
with MetSd in the control subjects. The effects of independent risk factors of the 
syndrome have been described, and so the inclusion of control group with single or 
coupled vascular risk factors may influence the results obtained. In our study, in 
which rigorous exclusion criteria were applied, the controls had none of the 
vascular risk factors included in the diagnosis of MetSd. We also performed a 
comprehensive neuropsychological assessment, using a case-control design to 
compare the effect of the syndrome in different cognitive domains. As our subjects 
showed normal MMSE scores and the effects of education and gender were 
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controlled, our findings may indicate a subtle initiation of vascular impairment, 
which can be followed up over time. Indeed, the discriminant analysis results 
showed that the CPT-II reaction time and the Blocks subtest of WAIS-III are the 
variables that best discriminate between patients and controls. We propose that 
these measures should be taken in account in clinical protocols, because they can 
provide information about the evolution of the neuropsychological profile in MetSd 
patients and the differences between this profile and that of normal ageing.  
While our findings are suggestive, the study is limited in several ways. The most 
important limitation is the sample size, due to the high comorbidity of MetSd and 
ageing with some of the exclusion criteria such as vascular pathology. Similarly, 
due to the sample size we were unable to study the effect of gender in depth. It 
would be particularly interesting to study the interaction effect of gender and age, 
and the associated risk of MetSd. 
Future studies with groups of intermediate subjects with one or two risk factors 
and larger sample sizes may establish whether MetSd really causes a syndromic 
effect in the central nervous system that is greater than the sum of its parts.   
In conclusion, MetSd patients show a specific neuropsychological profile. The 
detection of its specific manifestations appears to be the next step in preventing 
cognitive decline. We therefore propose that MetSd be included as a variable in 
research studies on cognitive impairment associated with ageing, in order to study 
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Table 1. Neuropsychological results of Metabolic Syndrome and Control Groups. Raw scores (Mean± SD, 
range and number of subjects). 
 
  Metabolic Syndrome   Control  
M (SD)Range (n)   M (SD) Range (n)   t/U p ESr  
 
RAVLT Total 46.07 (8.99)28-66(55) 48.23 (9.64)33-69(35)  -1.08† NS -  
RAVLT Del  9.51 (2.40)5-15(55) 10.34 (2.00)6-15 (35)  -1.71† NS -  
RAVLT RI 3.37 (1.89)0-8(54) 2.35   (1.77)0-7(34)  2.52† 0.014 0.27 
Faces I  35.42 (4.95)23-48(55) 37.74 (5.00)26-46(35)  -2.16† 0.033 0.24 
Forward D. 6.96  (1.81)4-13(55) 8.09  (1.88)4-12(34)  -2.81† 0.006 0.29 
Semantic F 18.55 (4.80)10-31(55) 21.43 (4.95)12-31(35)  -2.75† 0.007 0.28 
Phonetic F 12.67 (4.80)4-22(55) 14.09 (4.54)7-25 (35)  -1.39† NS - 
WCST Persev 16.38 (14.16)2-63(55) 11.14 (9.48)1-34 (35)  1.92† NS - 
WCST Cat 1.85 (1.08)0-3(55) 2.23 (0.97)0-3(35)  -1.67† NS - 
TMT B  131.70(72.25)50-385(43) 112.87(57.51)39-55(31)  1.20† NS - 
Stroop test 2.54 (8.52)(-18)-22 (53) 4.78 (8.45)(-12)-26 (35)  -1.21† NS - 
Arithmetic 9.44 (3.44)5-22(39) 11.88 (4.13)5-18(26)   325†† 0.014 0.32 
SDMT oral 33.67 (16.19)9-76(55) 38.29 (14.51)15-74(35)  -2.81†  0.006 0.15 
GPT DH  89.87 (27.72)59-221(55) 74.03 (15.39)62-233(34)  3.05† 0.003 0.33 
GPT NDH  101.02 (32.40)62-233(54) 82.29 (20.26)55-170(34)  528†† 0.001 0.36 
CPT-II RT 453.23 (63.30)305-557(42)414.57 (49.79)322-487 (26) 334††    0.007  0.33 
TMT A  52.73 (22.64)24-126(52) 46.45 (22.98)22-146(33)  1.24† NS - 
Facial Benton 47.18 (4.05)39-55(55) 48.00 (3.75)40-54(34)  -0.95† NS - 
Block  27.22 (11.74)10-54(55) 35.09 (11.45)12-59(35)  3.13†    0.002 0.32 
BNT  12.60 (1.38)8-15(55) 12.83 (1.12)10-15(35)  -0.82† NS - 
 
Note: RAVLT = Rey Auditory Verbal Learning Test, Del= Delayed, RI = retroactive interference; Faces I: 
Faces I subtest of Wechsler Memory scale III;  Forward D= Forward Digits subtest Wechsler Adult 
Intelligence Scale III;  F= Fluency; WCST = Wisconsin Card Sorting Test; Perserv= perseverative 
responses, Cat= number of Categories;  TMT B = Trail Making Test Part B;  Backward D = Backward Digits 
subtest of Wechsler Adult Intelligence Scale III;  Arithmetic= Arithmetic subtest of Wechsler Adult 
Intelligence Scale III; SDMT = Symbol Digit Modalities Test;  GPT = Grooved Pegboard Test, DH = 
Dominant Hand, NDH = Non Dominant Hand;  CPT-II RT = Continuous Performance Test Reaction time;  
TMT A = Trail Making Test Part A; Block= Block subtest of Wechsler Adult Intelligence Scale III;  
BNT= Boston Naming Test. † = t d' Students test; †† = U Mann Whitney test; ES r = Effect size r absolute 
value. NS= Non significant values. 
 
 
Supplementary data 1. Metabolic Syndrome Criteria. (Grundy et al., 2005) 
Metabolic Syndrome diagnosis requires 3 of 5 of the following criteria. 
 
Measure      Categorical Cutpoints   
Elevated waist circumference    ≥ 102 cm in men 
     ≥ 88 cm in women 
Elevated triglycerides     ≥ 150 mg/dL  
      or   
On drug treatment for elevated 
triglycerides 
Reduced HDL-Cholesterol    < 40 mg/dL in men   
      < 50 mg/dL in women 
      Or 
      On drug treatment for  
      reduced HDL-C.. 
Elevated blood pressure   ≥ 130 mm Hg systolic blood 
pressure    
 or  
 ≥ 85 mm Hg diastolic blood  
pressure 
or      
On antihypertensive drug 
treatment a patient with history 
of hypertension.  
Elevated fasting glucose     ≥ 100 mg/dL 
      or 
      On drug treatment for 
      elevated glucose.  
 
 
Supplementary data 2.  Demographic characteristics of Metabolic Syndrome 
group and control group.  
    
   Metabolic Syndrome  Control  
   M (SD)  Range   M (SD)   Range   
Age (years)  63.80 (7.28) 50-80   61.66 (7.69) 51-78  
Education (years) 8.55 (3.63)  1-16   10.20 (4.56) 1-16  
Vocabulary   37.71 (11.0) 12-58   40.97 (9.53) 24-60  
MMSE   28.94 (1.12)  26-30   29.31 (0.86) 27-30  
Praxis   8  (0) 8   8  (0) 8  
M: mean SD: Standard Deviation    
 
Metabolic Syndrome  Control  
Gender (M/F) 19/36     18/17 
Occupation Level 
 Low   37     17 
 Medium  10     9 
 High   8     9 
M: male, F: female 
 
Supplementary data 3.  Laboratory data of Metabolic Syndrome group and 
control group.  
 
Metabolic Syndrome  Control  
M (SD)  Range   M (SD)   Range   
 
Glucose (mg/dL) 112.03 (30.77) 76-238  86.97 (7.62) 66-99  
 
HDL-Cholesterol  53.26 (15.10) 25-98   67.78 (14.79) 40-111  
(mg/dL) 
 
Triglycerides  150.30 (87.41) 51-453  79.67 (25.79) 44-141  
(mg/dL) 
 
SBP (mmHg)  133.37 (15.90) 106-204   121.71 (8.40) 109-133  
 
DBP (mmHg)  78.31 (9.60) 58-104   75.26 (6.59) 58-83  
 
WC (cm)   104.91 (10.42) 88-133  85.45 (8.78) 68.5-101 
 
 
M: mean SD: Standard Deviation. SBP: systolic blood pressure. DBP: diastolic 
blood pressure. WC: Waist Circumference.  
 
Supplementary data 4. Discriminat analysis.  
   
Wilkins λ Chi2  p  Variables  Coefficients 
(Standardized) 
0.787  13.861 0.001  CPT-II RT  0.741   
      Block WAIS-III -0.647 
 
CPT-II RT = Continuous Performance Test II Reaction Time; WAIS-III = Wechsler 
Adult Intelligence Scale III. 
       
     
 
